Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Linagliptin/Metformin FDC (2.5/500 mg) vs Single Agents
NCT02221414Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2010
- Primary completion
- Mar 2010
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of linagliptin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to 72 hours, Maximum measured concentration at 72 hours and 1 more. Started Jan 2010; status: completed.
02
Drugs
linagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02221414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221414.